NEUROD6

Across TCGA pan-cancer cohorts, NEUROD6 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of NEUROD6’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where NEUROD6 RNA is repressed in tumor relative to normal tissue. In most cancer types NEUROD6 is over-expressed in tumor, although a few such as LIHC and COAD show the opposite, repressed pattern.

LIHC, COAD, and STAD are the cancer types where NEUROD6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NEUROD6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	−0.027	.001	4	view →
COAD	All	II,III,IV	−0.008	.049	2	view →
STAD	Female	III,IV	−0.065	.005	1	view →
CHOL	All	All	−0.018	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

NEUROD6–LIHC

Open the LIHC breakdown →